Dr. Agarwal’s Group of Eye Hospitals Raises Rs. 215 Crores from CDC Group
Chennai, 18th December 2019: Dr. Agarwal’s Healthcare Ltd. (DAHCL) has raised Rs. 215 crores of debt from CDC Group to expand the geographical footprint of the eye care chain across India, Africa and South Asia along with significant investments in latest technology for super specialty eye-care. The group has recently set up its first hospital in Mumbai in partnership with Advanced Eye Institute in Navi Mumbai. Dr. Agarwal’s Healthcare Ltd. (DAHCL) had raised Rs. 270 crore investment from Temasek, a global investment company headquartered in Singapore earlier this year.
CDC Group is a development finance institution funded by the UK government. The CDC group has primarily focused on investing in developing countries for the past 70 years across sectors such as healthcare, financial services, infrastructure, manufacturing, food and agriculture, construction and real estate, education, etc. Its direct investments in healthcare in India include Rainbow Hospitals, CARE Hospitals, Asian Institute of Medical Sciences and Narayana Health.
“CDC’s investment will immensely help in furthering our vision in bringing affordable world class eye-care services to patients across the globe.” said Prof. (Dr.) Amar Agarwal, (MS, FRCS, FRC Ophth), Chairman, Dr. Agarwal’s Group of Eye Hospitals.
Dr. Adil Agarwal, CEO, Dr. Agarwal’s Group of Eye Hospitals said that “The investment will be used to support the business through its next phase of growth, including the acquisition of small hospitals and chains. With CDC’s focus on Africa and South Asia, the group is looking to bolster its international presence. We are also looking to expand aggressively in Maharashtra, Kerala and central India besides penetrating deeper into our existing markets. We will also be investing more in cutting edge technology such as SMILE, Femto Laser and Robotic Cataract Surgery across our centers.”
The Dr. Agarwal’s group has been at the forefront of innovation in the field of Ophthalmology with procedures such as Glued IOL (to treat patients with complicated lens problems), PDEK (an ultra-modern form of Corneal transplants) and PhakoNIT (Removal of Cataract through a sub 1mm incision). The latest invention from the group is a novel technique called “Single-Pass Four Throw” (SFT) along with “Pin Hole Pupilloplasty”, which is also referred to as PPP. The surgical technique is being used to help in pupillary reconstruction as well as to treat complicated cases of Narrow Angle Glaucoma. There is also a lot of focus on education and training and the group attracts doctors from across the globe for its training programs; They also offer a DNB (post-graduate) program and various fellowship programs to train young, budding surgeons.
“With CDC’s expertise and relentless focus on developing markets, the group is poised to move towards greater heights.” said Mr. Suresh Prabhala, ADV Partners. A fund advised by ADV Partners invested Rs 270 crores in Dr Agarwal’s HealthCare Ltd in 2016 and has been a key component of the company’s board and growth story.
Srini Nagarajan, Managing Director and Head of Asia CDC Group said, “Our 70 years’ plus track record of investing responsibly across Asia and Africa will help drive Dr. Agarwal’s Group’s expansion plans. Furthermore, we will share our broad healthcare sector experience with this ambitious management team, helping to bring eyecare to many people in India, Africa and beyond. We look forward to embarking on a prosperous relationship with Dr. Agarwal’s Group.” Veda Corporate Advisors, a leading mid-market investment bank advised the company on the transaction.
About Dr Agarwal’s
Dr. Agarwal’s Group of Eye Hospitals started as a single facility in Chennai in the year 1957. Now the hospital chain has a total presence of 91 hospitals with 77 centers in India (across 12 states) and 14 hospitals in Africa (across 10 countries). A tertiary eye care center set up at Mauritius in 2010 marked its entry into the international market.
The group offers a complete gamut of eye care services such as Cataract, Laser correction, Vitreo-Retinal Surgery, Corneal transplantation, Glaucoma and Squint at its centers. In addition to this, super-specialty eye care services such as Pediatric ophthalmology, Ocular Oncology, Neuro ophthalmology, Uvea and Oculoplasty are also offered at its tertiary hubs.
CDC Group is the world’s first Development Finance Institution with over 70 years of experience of successfully supporting the sustainable, long-term growth of businesses in South Asia and Africa.
CDC is a leading player in the fight against climate change and a UK champion of the UN’s Sustainable Development Goals – the global blueprint to achieve a better and more sustainable future for us all.
CDC has investments in over 1,200 businesses in emerging economies and a total portfolio value of £5.8bn. This year CDC will invest over $1.5bn in companies in Africa and Asia with a focus on fighting climate change, empowering women and creating new jobs and opportunities for millions of people.
CDC is funded by the UK government and all proceeds from its investments are reinvested to improve the lives of millions of people in Africa and South Asia.
CDC’s expertise makes it the perfect partner for companies and private investors looking to devote capital to making a measurable environmental and social impact in countries most in need of investment.